Search

Your search keyword '"Lv, Ruichan"' showing total 261 results
Start Over Author "Lv, Ruichan"
261 results on '"Lv, Ruichan"'

12. Polyethylenimine-Coated Pt–Mn Nanostructures for Synergistic Photodynamic/Photothermal/Chemodynamic Tumor Therapy.

Author

Li, Bixiao, Xu, Danyang, Chen, Yitong, Li, Wenjing, Liu, Hanyu, Ansari, Anees A., and Lv, Ruichan

Abstract

How to develop antitumor nanodrugs with low toxicity and a good curative effect is an urgent problem in the current biomedicine field. In this work, different proposed composites were simulated by the finite difference time domain (FDTD) and COMSOL, including the material element, refractive index, particle size, and shape. Also, different machine learning algorithms are utilized to predict the absorbance at the near-infrared laser of 980 nm of different materials. Through train, validation, and test, the prediction of the as-synthesized Pt–Mn has high absorbance. Then, inorganic Pt–Mn was coated with PEI in order to improve their biocompatibility. Pt–Mn nanoparticles can generate ROS under the single 980 nm laser irradiation as a photodynamic therapy (PDT) agent and as a photothermal therapy (PTT) agent to heat the cells with a photothermal conversion efficiency of 23.6%. In addition, the electrochemical and in vitro chemodynamic therapy (CDT) experiments prove that Pt–Mn nanozymes could mimic the activity of peroxidase and enhance the Fenton reaction, thereby catalyzing excess H2O2 to produce hydroxyl free radicals and illustrating the potential to induce tumor cell apoptosis as the CDT agent in a weakly acidic tumor environment to complete high-efficiency chemokinetic therapy. Finally, Pt–Mn–PEI nanoparticles were used for PDT/PTT/CDT and the immune checkpoint inhibitor of anti-PD-L1 is injected in order to obtain the assistant immunotherapy, providing a potential choice to anticancer through effective synergistic cancer therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Exosome-based rare earth nanoparticles for targeted in situand metastatic tumor imaging with chemo-assisted immunotherapyElectronic supplementary information (ESI) available: The elemental mapping overlay of the E-RENPs. The UCL fluorescence imaging of RENPs upon irradiation with a 980 nm laser. The biostability photographs of RENPs and DOX/2DG@RENPs. The fluorescence imaging of RENPs was detected by AM/PI for dead and living cells. The hemolysis rate of the RENPs. The graph of DOX was added with different weights. The DOX release rate curves of 2DG/DOX@RENPs. Fluorescence microscopy images of A549 cells co-incubated with E-RENPs of 4T1 cells or HeLa cells, respectively. CLSM images of exosomes from different cell sources co-incubated with different cells. CLSM images of A549 cells incubated with RENPs at different time points. CLSM images of Cal27 cells incubated with E-RENPs from Cal27 cells at different time points. CLSM images of A549 cells incubated with E-RENPs from Cal27 cells a

Author

Lin, Bi, Wang, Yanxing, Zhao, Kun, Lü, Wei-Dong, Hui, Xin, Ma, Yaqun, and Lv, Ruichan

Abstract

In this research, a tumor exosome system DOX/2DG@E-RENPs with good biocompatibility, low immunogenicity, and a high targeting effect was proposed for theranostics with high chemo-/starvation/immunotherapy efficiency. DOX and 2-deoxy-d-glucose (DOX/2DG) together with rare earth nanoparticles (RENPs) can be simultaneously carried on the exosome by endocytosis of tumor cells and then exocytosis in vitro. This platform has a good monodispersity with an average size of 70 nm, and the system can emit upconversion luminescence and NIR II luminescence under a single NIR laser. In particular, this exosome can target homing cancer cells and kill the origin tumor cells. The strong targeting effect was proved by different cell lines with exosomes from different orthogonal cells (normal/cancer cells and human/mouse sources, respectively), and the in vivoNIR II imaging guided targeted cancer imaging and liver metastases can be realized by intravenous injection of E-RENPs. Furthermore, the good targeted therapeutic effect and in vivoNIR II imaging and metastases of this platform can be proved. The chemotherapy, starvation therapy, and immunotherapy (immune checkpoint inhibitors of an anti-PD-L1 antibody) could achieve effective synergistic therapy for lung adenocarcinoma, and the immunotherapy can be further proved by the clinical data. This will provide a new strategy for the precise targeting and treatment of tumors.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results